Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 3/2015

01.09.2015 | Review Article

Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis

verfasst von: F. Petrelli, E. Pezzica, M. Cabiddu, A. Coinu, K. Borgonovo, M. Ghilardi, V. Lonati, D. Corti, S. Barni

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Tumour budding is defined as the presence of isolated or small clusters of malignant cells at the invasive edge of the tumour. It is considered a negative prognostic factor in colorectal cancer (CRC) and is associated with a poor outcome and adverse pathological features. Here, we report a meta-analysis of the association of tumour budding and survival in stage II CRC patients.

Methods

PubMed, EMBASE, Web of Science and SCOPUS were searched for studies that assessed the relationship between tumour budding and 5-year overall survival (OS) in stage II CRC patients. Published data were extracted and used to compute odds ratios (ORs) for death at 5 years and hazard ratios (HRs) for survival amongst patients with respect to the extent of tumour budding, using multivariate analysis. Data were pooled using the Mantel–Haenszel random effect model.

Results

We analysed 12 studies that included a total of 1652 patients. High-grade budding was associated with worse OS at 5 years (OR for death, 6.25; 95 % confidence interval [CI], 4.04–9.67; P < 0.00001). The absolute difference in 5-year OS was −25 % (95 % CI, −18– − 33 %, P < 0.00001). It was particularly noteworthy that the presence of high-grade budding was associated with an increased risk of death (HR for death, 3.68; 95 % CI, 2.16–6.28, P < 0.00001).

Conclusions

Tumour budding is associated with worse survival in stage II CRC, in particular in pT3N0M0 patients. It could therefore potentially be used when deciding whether to administer adjuvant chemotherapy in high-risk node negative CRC patients.
Literatur
1.
Zurück zum Zitat Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9.CrossRef Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9.CrossRef
2.
Zurück zum Zitat Wu X, Zhang J, He X, et al. Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. J Gastrointest Surg. 2012;16:646–55.PubMedCrossRef Wu X, Zhang J, He X, et al. Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. J Gastrointest Surg. 2012;16:646–55.PubMedCrossRef
4.
Zurück zum Zitat Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26. Erratum in: J Clin Oncol. 2010 Oct 20;28(30):4664.PubMedCentralPubMedCrossRef Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26. Erratum in: J Clin Oncol. 2010 Oct 20;28(30):4664.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Okuyama T, Oya M, Ishikawa H. Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma. J Surg Oncol. 2003;83:42–7.PubMedCrossRef Okuyama T, Oya M, Ishikawa H. Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma. J Surg Oncol. 2003;83:42–7.PubMedCrossRef
6.
Zurück zum Zitat Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II welldifferentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum. 2003;46:1400–6.PubMedCrossRef Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II welldifferentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum. 2003;46:1400–6.PubMedCrossRef
7.
Zurück zum Zitat Nakamura T, Mitomi H, Kanazawa H, et al. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum. 2008;51:568–72.PubMedCrossRef Nakamura T, Mitomi H, Kanazawa H, et al. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum. 2008;51:568–72.PubMedCrossRef
8.
Zurück zum Zitat Yasuda K, Inomata M, Shiromizu A, et al. Risk factors for occult lymph node metastasis of colorectal cancer invading the submucosa and indications for endoscopic mucosal resection. Dis Colon Rectum. 2007;50:1370–6.PubMedCrossRef Yasuda K, Inomata M, Shiromizu A, et al. Risk factors for occult lymph node metastasis of colorectal cancer invading the submucosa and indications for endoscopic mucosal resection. Dis Colon Rectum. 2007;50:1370–6.PubMedCrossRef
9.
Zurück zum Zitat Prall F, Nizze H, Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology. 2005;47:17–24.PubMedCrossRef Prall F, Nizze H, Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology. 2005;47:17–24.PubMedCrossRef
10.
Zurück zum Zitat Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 2010;1:651–61.PubMedCentralPubMed Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 2010;1:651–61.PubMedCentralPubMed
11.
Zurück zum Zitat Morodomi T, Isomoto H, Shirouzu K, et al. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer. 1989;63:539–43.PubMedCrossRef Morodomi T, Isomoto H, Shirouzu K, et al. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer. 1989;63:539–43.PubMedCrossRef
12.
Zurück zum Zitat Shinto E, Jass JR, Tsuda H, et al. Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia. Dis Colon Rectum. 2006;49:1422–30.PubMedCrossRef Shinto E, Jass JR, Tsuda H, et al. Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia. Dis Colon Rectum. 2006;49:1422–30.PubMedCrossRef
13.
Zurück zum Zitat Liberati A, Altman D, Tetzlaff J. The PRISMA statement for reportingsystematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.PubMedCentralPubMedCrossRef Liberati A, Altman D, Tetzlaff J. The PRISMA statement for reportingsystematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Lai YH, Wu LC, Li PS, et al. Tumour budding is a reproducible index for risk stratification of patients with Stage II colon cancer. Color Dis. 2014;16(4):259–64.CrossRef Lai YH, Wu LC, Li PS, et al. Tumour budding is a reproducible index for risk stratification of patients with Stage II colon cancer. Color Dis. 2014;16(4):259–64.CrossRef
15.
Zurück zum Zitat Betge J, Kornprat P, Pollheimer MJ, et al. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann Surg Oncol. 2012;19(12):3706–12.PubMedCrossRef Betge J, Kornprat P, Pollheimer MJ, et al. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann Surg Oncol. 2012;19(12):3706–12.PubMedCrossRef
16.
Zurück zum Zitat Canney AL, Kevans D, Wang LM, et al. Stage II colonic adenocarcinoma: a detailed study of pT4N0 with emphasis on peritoneal involvement and the role of tumour budding. Histopathology. 2012;61(3):488–96.PubMedCrossRef Canney AL, Kevans D, Wang LM, et al. Stage II colonic adenocarcinoma: a detailed study of pT4N0 with emphasis on peritoneal involvement and the role of tumour budding. Histopathology. 2012;61(3):488–96.PubMedCrossRef
17.
Zurück zum Zitat Kevans D, Wang LM, Sheahan K, et al. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status. Int J Surg Pathol. 2011;19(6):751–60.PubMedCrossRef Kevans D, Wang LM, Sheahan K, et al. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status. Int J Surg Pathol. 2011;19(6):751–60.PubMedCrossRef
18.
Zurück zum Zitat Tanaka M, Hashiguchi Y, Ueno H, Hase K, Mochizuki H. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum. 2003;46(8):1054–9.PubMedCrossRef Tanaka M, Hashiguchi Y, Ueno H, Hase K, Mochizuki H. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum. 2003;46(8):1054–9.PubMedCrossRef
19.
Zurück zum Zitat Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33(1):134–41.PubMedCrossRef Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33(1):134–41.PubMedCrossRef
20.
Zurück zum Zitat Yoshida K, Yoshimatsu K, Otani T, Yokomizo H, Ogawa K. The depth of tumor invasion beyond the outer border of the muscularis propria as a prognostic factor for T3 rectal/rectosigmoid cancer. Anticancer Res. 2008;28(3B):1773–8.PubMed Yoshida K, Yoshimatsu K, Otani T, Yokomizo H, Ogawa K. The depth of tumor invasion beyond the outer border of the muscularis propria as a prognostic factor for T3 rectal/rectosigmoid cancer. Anticancer Res. 2008;28(3B):1773–8.PubMed
21.
Zurück zum Zitat Park KJ, Choi HJ, Roh MS, Kwon HC, Kim C. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum. 2005;48(8):1597–602.PubMedCrossRef Park KJ, Choi HJ, Roh MS, Kwon HC, Kim C. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum. 2005;48(8):1597–602.PubMedCrossRef
22.
Zurück zum Zitat Choi HJ, Park KJ, Shin JS, et al. Tumor budding as a prognostic marker in stage-III rectal carcinoma. Int J Color Dis. 2007;22:863–8.CrossRef Choi HJ, Park KJ, Shin JS, et al. Tumor budding as a prognostic marker in stage-III rectal carcinoma. Int J Color Dis. 2007;22:863–8.CrossRef
23.
Zurück zum Zitat Guzinska-Ustymowicz K. The role of tumour budding at the front of invasion and recurrence of rectal carcinoma. Anticancer Res. 2005;25:1269–72.PubMed Guzinska-Ustymowicz K. The role of tumour budding at the front of invasion and recurrence of rectal carcinoma. Anticancer Res. 2005;25:1269–72.PubMed
24.
Zurück zum Zitat Ha SS, Choi HJ, Park KJ, et al. Intensity of tumor budding as an index for the malignant potential in invasive rectal carcinoma. Cancer Res Treat. 2005;37:177–82.PubMedCentralPubMedCrossRef Ha SS, Choi HJ, Park KJ, et al. Intensity of tumor budding as an index for the malignant potential in invasive rectal carcinoma. Cancer Res Treat. 2005;37:177–82.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Hase K, Shatney C, Johnson D, et al. Prognostic value of tumor ‘budding’ in patients with colorectal cancer. Dis Colon Rectum. 1993;36:627–35.PubMedCrossRef Hase K, Shatney C, Johnson D, et al. Prognostic value of tumor ‘budding’ in patients with colorectal cancer. Dis Colon Rectum. 1993;36:627–35.PubMedCrossRef
26.
Zurück zum Zitat Homma Y, Hamano T, Otsuki Y, et al. Severe tumor budding is a risk factor for lateral lymph node metastasis in early rectal cancers. J Surg Oncol. 2010;102:230–4.PubMedCrossRef Homma Y, Hamano T, Otsuki Y, et al. Severe tumor budding is a risk factor for lateral lymph node metastasis in early rectal cancers. J Surg Oncol. 2010;102:230–4.PubMedCrossRef
27.
Zurück zum Zitat Kajiwara Y, Ueno H, Hashiguchi Y, et al. Risk factors of nodal involvement in T2 colorectal cancer. Dis Colon Rectum. 2010;53:1393–9.PubMedCrossRef Kajiwara Y, Ueno H, Hashiguchi Y, et al. Risk factors of nodal involvement in T2 colorectal cancer. Dis Colon Rectum. 2010;53:1393–9.PubMedCrossRef
28.
Zurück zum Zitat Kanazawa H, Mitomi H, Nishiyama Y, et al. Tumour budding at invasive margins and outcome in colorectal cancer. Color Dis. 2008;10:41–7. Kanazawa H, Mitomi H, Nishiyama Y, et al. Tumour budding at invasive margins and outcome in colorectal cancer. Color Dis. 2008;10:41–7.
29.
Zurück zum Zitat Kazama S, Watanabe T, Ajioka Y, et al. Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2. Br J Cancer. 2006;94:293–8.PubMedCentralPubMedCrossRef Kazama S, Watanabe T, Ajioka Y, et al. Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2. Br J Cancer. 2006;94:293–8.PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Lugli A, Karamitopoulou E, Panayiotides I, et al. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer. Br J Cancer. 2009;101:1382–92.PubMedCentralPubMedCrossRef Lugli A, Karamitopoulou E, Panayiotides I, et al. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer. Br J Cancer. 2009;101:1382–92.PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Masaki T, Matsuoka H, Sugiyama M, et al. Tumor budding and evidence-based treatment of T2 rectal carcinomas. J Surg Oncol. 2005;92:59–63.PubMedCrossRef Masaki T, Matsuoka H, Sugiyama M, et al. Tumor budding and evidence-based treatment of T2 rectal carcinomas. J Surg Oncol. 2005;92:59–63.PubMedCrossRef
32.
Zurück zum Zitat Sohn DK, Chang HJ, Park JW, et al. Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type. J Clin Pathol. 2007;60:912–5.PubMedCentralPubMedCrossRef Sohn DK, Chang HJ, Park JW, et al. Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type. J Clin Pathol. 2007;60:912–5.PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Ueno H, Mochizuki H, Hashiguchi Y, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004;127:385–94.PubMedCrossRef Ueno H, Mochizuki H, Hashiguchi Y, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004;127:385–94.PubMedCrossRef
34.
Zurück zum Zitat Ueno H, Murphy J, Jass JR, et al. Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002;40:127–32.PubMedCrossRef Ueno H, Murphy J, Jass JR, et al. Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002;40:127–32.PubMedCrossRef
36.
Zurück zum Zitat Yamauchi H, Togashi K, Kawamura YJ, et al. Pathological predictors for lymph node metastasis in T1 colorectal cancer. Surg Today. 2008;38:905–10.PubMedCrossRef Yamauchi H, Togashi K, Kawamura YJ, et al. Pathological predictors for lymph node metastasis in T1 colorectal cancer. Surg Today. 2008;38:905–10.PubMedCrossRef
37.
Zurück zum Zitat Wang HS, Liang WY, Lin TC, et al. Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis. Dis Colon Rectum. 2005;48:1182–92.PubMedCrossRef Wang HS, Liang WY, Lin TC, et al. Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis. Dis Colon Rectum. 2005;48:1182–92.PubMedCrossRef
38.
Zurück zum Zitat Ohtsuki K, Koyama F, Tamura T, et al. Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res. 2008;28:1831–6.PubMed Ohtsuki K, Koyama F, Tamura T, et al. Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res. 2008;28:1831–6.PubMed
39.
Zurück zum Zitat Suzuki A, Togashi K, Nokubi M, et al. Evaluation of venous invasion by Elastica van Gieson stain an tumor budding predicts local and distant metastases in patients with T1 stage colorectal cancer. Am J Surg Pathol. 2009;33:1601–7.PubMedCrossRef Suzuki A, Togashi K, Nokubi M, et al. Evaluation of venous invasion by Elastica van Gieson stain an tumor budding predicts local and distant metastases in patients with T1 stage colorectal cancer. Am J Surg Pathol. 2009;33:1601–7.PubMedCrossRef
40.
Zurück zum Zitat Syk E, Lenander C, Nilsson PJ, et al. Tumour budding correlates with local recurrence of rectal cancer. Color Dis. 2011;13:255–62.CrossRef Syk E, Lenander C, Nilsson PJ, et al. Tumour budding correlates with local recurrence of rectal cancer. Color Dis. 2011;13:255–62.CrossRef
41.
Zurück zum Zitat Bartley AN, Hamilton SR, Alsabeh R, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. Arch Pathol Lab Med. 2014;138(2):166–70.PubMedCrossRef Bartley AN, Hamilton SR, Alsabeh R, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. Arch Pathol Lab Med. 2014;138(2):166–70.PubMedCrossRef
42.
Zurück zum Zitat Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 2012;25(10):1315–25.PubMedCrossRef Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 2012;25(10):1315–25.PubMedCrossRef
43.
Zurück zum Zitat Koelzer VH, Zlobec I, Berger MD, et al. Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study. Virchows Arch. 2015;21. Koelzer VH, Zlobec I, Berger MD, et al. Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study. Virchows Arch. 2015;21.
44.
Zurück zum Zitat Horcic M, Koelzer VH, Karamitopoulou E, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol. 2013;44(5):697–705.PubMedCrossRef Horcic M, Koelzer VH, Karamitopoulou E, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol. 2013;44(5):697–705.PubMedCrossRef
Metadaten
Titel
Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis
verfasst von
F. Petrelli
E. Pezzica
M. Cabiddu
A. Coinu
K. Borgonovo
M. Ghilardi
V. Lonati
D. Corti
S. Barni
Publikationsdatum
01.09.2015
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 3/2015
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-015-9716-1

Weitere Artikel der Ausgabe 3/2015

Journal of Gastrointestinal Cancer 3/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.